若生智能
Drug Database
ME

meningococcal B vaccine (rLP 2086 / PF05212366 / MnB rLP2086)

✓ Approved

Pfizer, Inc. · · 重组蛋白

什么是 meningococcal B vaccine？

meningococcal B vaccine 是一种重组蛋白，由Pfizer, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名rLP 2086, PF05212366, MnB rLP2086
公司Pfizer, Inc.
药物类别重组蛋白, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Pfizer, Inc.

作用机制

分子靶点

meningococcal B vaccine 作用于 1 个分子靶点：

()
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

meningococcal B vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedOpen forum infectious diseases2026-08-05

A Multidesign Study of 4CMenB Vaccine Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People.

McMillan Mark M, Wang Bing B, Krause Vicki V, Greenwood-Smith Belinda B et al.

Emerging evidence suggests the 4CMenB vaccine provides moderate protection against gonorrhea, likely due to the close genetic relationship between Neisseria gonorrhoeae and Neisseria meningitidis. 4CMenB has an impact on unencapsulated meningococcal oropharyngeal carriage, where outer membrane proteins are exposed, potentially exerting selective pressure on these strains. We assessed the impact of 4CMenB immunization on gonorrhea disease and oropharyngeal meningococcal carriage among adolescents in the Northern Territory (NT), Australia. All adolescents aged 14-19 years in the NT were eligible to receive two doses of 4CMenB between 2021 and 2023. Participants had oropharyngeal swabs collected at baseline and 12 months. Vaccine effectiveness (VE) against gonorrhea was assessed using linked notification and immunization data. A Cox proportional hazards model stratified by sex, age, and geography estimated VE. Mixed-effects logistic regression estimated postvaccination odds of meningococcal carriage. A total of 30 650 adolescents were included in the VE analysis, with 9.6% receiving 2 doses of 4CMenB, and 42.4% of the population identifying as Aboriginal or Torres Strait Islanders. Gonococcal notifications were reduced in vaccinated adolescents (VE 38.4%, 95% CI: 18.6-53.4). Overall, meningococcal carriage increased from 4.0% to 6.2% (OR 1.68, 95% CI: 1.14-2.48), driven by genogroup B and nongroupable strains. Carriage of disease-associated meningococci remained stable. 4CMenB confers modest protection against gonorrhea in a real-world setting with higher adolescent disease prevalence. These findings are important for women, considering infections are often asymptomatic and have the potential for serious complications. The NT has now introduced a 4CMenB infant and adolescent program.

PMID 42553573
阅读全文 →
PubMedClinical kidney journal2026-08-05

Lipid parameters but not inflammatory indices predict hepatitis B vaccine responses in hemodialysis patients.

Ekici Hilal H, Mirza Arzu A, Baltacı Sevgi S, Eren Davut D et al.

Hepatitis B virus (HBV) vaccination is essential in hemodialysis (HD) populations, yet seroprotection remains suboptimal. Inflammation-related hematologic indices are frequently used in clinical practice, but their ability to predict HBV vaccine response in HD patients is uncertain. We evaluated clinical and laboratory determinants of HBV vaccine response, with a focus on lipid-derived indices and inflammatory ratios. In this multicenter retrospective study, adult HD patients followed between 2015 and 2025 who received at least three doses of HBV vaccine and had available anti-HBs measurements were included (n = 341). Vaccine response was defined as anti-HBs ≥10 IU/L; non-response as <10 IU/L. Neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), monocyte-to-lymphocyte (MLR), neutrophil percentage-to-albumin ratio (NPAR), and lipid ratios (TG/HDL, TC/HDL, LDL/HDL) were calculated. Additional analyses using percentile-based categorization of NPAR confirmed the absence of a significant association with vaccine response. Multivariable logistic regression and receiver operating characteristic analyses were performed. After the primary vaccination series, seroprotection was 77.4% and increased to 88.6% after revaccination/boosters; it declined to 78.3% at 1 year and 69.2% at 2 years. Non-responders were older and had higher triglyceride levels and lower HDL cholesterol levels. In contrast, inflammatory indices (NLR, PLR, MLR, and NPAR) did not differ significantly between groups. These indices also demonstrated limited discriminative ability for predicting vaccine response. In multivariable analysis, HDL cholesterol remained positively associated with vaccine response [odds ratio (OR): 1.046, 95% confidence interval (CI): 1.006-1.086, P = .022], and triglyceride levels were negatively associated with vaccine response (OR: 0.992, 95% CI: 0.984-0.999, P = .024). The TG/HDL ratio showed borderline statistical significance (OR: 1.235, 95% CI: 0.983-1.551, P = .070), suggesting a potential but limited contribution to vaccine response prediction. In HD patients, hematologic inflammatory indices were not informative for HBV vaccine response, whereas an atherogenic lipid profile-particularly lower HDL and higher triglycerides-showed a consistent association. Lipid parameters may support risk stratification and tailored post-vaccination monitoring strategies.

PMID 42553896
阅读全文 →
PubMedFrontiers in global women's health2026-08-05

Awareness, factual knowledge, attitudes, and acceptability of human papillomavirus vaccination among adult women in Palestine: a cross-sectional study.

Amro Alhareth M AM, Safadi Leen M LM, Fahoum Shahd R SR, Deeb Salahaldeen S et al.

Human papillomavirus (HPV) is a major preventable cause of cervical cancer, yet awareness and uptake of HPV vaccination remain suboptimal in many settings. Evidence regarding women's HPV-related awareness, factual knowledge, and vaccine acceptability in Palestine remains limited. This study assessed awareness, factual knowledge, attitudes, self-reported uptake, willingness, and perceived barriers related to HPV infection and HPV vaccination among adult women in Palestine. A cross-sectional online survey was conducted between October 2025 and February 2026 among women aged ≥18 years residing in Palestine. The questionnaire assessed sociodemographic characteristics, HPV and HPV vaccine awareness, factual knowledge, attitudes, vaccine uptake, willingness to receive or recommend vaccination, and perceived barriers. A 12-item factual knowledge score was calculated, and higher factual knowledge was defined as ≥7 correct responses. Descriptive statistics, subgroup analyses, and multivariable logistic regression were performed. Among 424 adult women included in the final analysis, 220 (51.9%) had heard of HPV and 146 (34.4%) had heard of the HPV vaccine. The mean factual knowledge score was 4.03 ± 2.72 out of 12, and 90 participants (21.2%) had higher factual knowledge. Self-reported HPV vaccine uptake was low (13.0%), whereas willingness to receive the vaccine was higher (55.2%). Lack of awareness (55.8%) and concern about vaccine safety (22.8%) were the most frequently reported barriers among unvaccinated women. In expanded adjusted analyses, prior HPV awareness, prior HPV vaccine awareness, and more supportive HPV-vaccination attitudes were independently associated with higher factual knowledge. Higher factual knowledge and supportive attitudes were associated with self-reported vaccine uptake, while willingness among unvaccinated women was most strongly associated with supportive vaccination attitudes. Adult women in Palestine demonstrated limited HPV-related awareness and low factual knowledge, together with low self-reported HPV vaccine uptake. The gap between willingness and uptake, combined with the predominance of awareness and safety concerns as reported barriers, suggests a need for culturally appropriate education, provider-led counseling, and improved access to reliable HPV vaccine information. Findings should be interpreted cautiously given the cross-sectional design and online convenience sampling.

PMID 42553322
阅读全文 →
PubMedInternal medicine journal2026-08-05

Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.

Tharmaraj Dhakshayini D, Naidu Paayal P, Baptista Mohana M, McBride Sarah S et al.

Kidney transplant recipients (KTRs) disproportionately experience severe COVID-19 infections. We previously identified concern regarding vaccine-induced rejection as a barrier to vaccine uptake. This study assesses COVID-19 vaccine uptake, infection outcomes and allograft rejection in KTRs during the delta and omicron waves (BA.1/BA.2). This cohort study included all adult KTRs with a functioning allograft at 22 March 2021 at our centre. KTR and vaccination-related risk factors for the primary outcome of severe COVID-19 infection (requiring hospitalisation) and the secondary outcomes of death and all COVID-19 infections were assessed using Cox proportional hazards models. Rejection risk following infection/vaccination was also assessed. Of the 986 included KTRs, there were 333 (33.8%) COVID-19 infections, 79 (23.7%) severe infections and 13 deaths (n = 13/333, 3.9%). Vaccine number was the most significant modifiable predictor of severe infection (adjusted hazards ratio, per additional dose, 0.5; 95% confidence interval, 0.40-0.65, P < 0.001) and death. While older age also predicted severe infection and death, lower estimated glomerular filtration rate, history of diabetes and previous allograft rejection predicted severe infection. Male gender was the only predictor of all infections. Mycophenolate dose, prednisolone use and vaccine type did not predict infection or severe disease. Infections and vaccinations did not increase the risk of rejection. KTRs should be encouraged to be optimally vaccinated to prevent severe disease and can be reassured about the low risk of allograft rejection. Risk factors that compound the state of immunocompromise and severe COVID-19 infections should prompt vigilance and targeted interventions to mitigate these risks.

PMID 42554002
阅读全文 →
PubMedPLoS computational biology2026-08-05

Quantifying the impact of vaccination on pertussis dynamics in Sweden.

Brett Tobias S TS, Tredennick Andrew A, Briga Michael M, Coudeville Laurent L et al.

The last few decades have witnessed a resurgence in pertussis notifications in a number of countries with high vaccine coverage, including Sweden. The underlying causes of the resurgence have been the subject of much scientific debate. To arbitrate among the putative drivers of the resurgence in Sweden, we formulated a mechanistic transmission model which we fit to age-structured time-series notifications data via likelihood maximisation. Given our model, we find the data are best explained by the combined effects of a low basic reproductive number, incomplete (leaky) DTaP-derived immunity, a much lower reporting probability of infections in older individuals and waning of vaccine-derived immunity. In addition, our modelling explains the post-2014 resurgence as a combination of two factors. First, a dynamical transient known as the honeymoon effect, in which a rebound in transmission follows after a rapid decrease in the average population susceptibility. Second, an increase in the infection reporting probability from 2014 onwards, likely due to the use of new laboratory testing methods. Additionally, we used our fitted transmission model to reconstruct indirect protective effects of vaccination. Our results suggest immunization prevents about 50% of potential infections in individuals too young to receive vaccination. However, our statistical inference demonstrates that pertussis elimination is not possible with routine immunization using acellular vaccines due to the combined effects of vaccine leakiness and waning immunity.

PMID 42550879
阅读全文 →
PubMedFrontiers in immunology2026-08-05

Effectiveness of varicella vaccine during a varicella outbreak in a Chinese senior high school: a retrospective cohort study.

Xu Nani N, Wu Liting L, Deng Xuan X, Shu Xin X et al.

To evaluate the vaccine effectiveness (VE) of single-dose and two-dose varicella vaccine (VarV) among senior high school students during a varicella outbreak in China, and provide recommendations for vaccination strategy optimization. A retrospective cohort study was conducted among students in a senior high school in China during a varicella outbreak from July 23 to November 8, 2024. The history of varicella disease, the immunization history of VarV and the incidence during the outbreak among all students in the school were surveyed. Kaplan-Meier methods were used to estimate the cumulative varicella-free survival rate among students with different immunization histories during the outbreak, and the log-rank test was used to compare the survival curves across the five groups. VE was calculated based on attack rates among students with different vaccination doses and intervals since last vaccination. Post-exposure vaccination VE was also assessed. Logistic regression analysis was performed to identify factors associated with varicella infection during the outbreak, and odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Among the 1,862 students present during the outbreak, the overall varicella attack rate was 6.29%. Kaplan-Meier analysis showed significant differences in cumulative varicella-free survival among the different immunization groups (χ² = 297.913, df = 4, P < 0.001). Single-dose varicella vaccine (VarV) coverage was 28.24% (475/1682), and two-dose coverage was 66.23% (1114/1682). Compared with unvaccinated individuals, VE with 95% CI was 32.14% (-54.37%- 70.17%) for 1-dose recipients and 94.74% (88.62%-97.57%) for 2-dose recipients. Among 1-dose recipients, VE was 90.48% (17.22%-98.90%) and 18.68% (-86.86%- 64.61%) for those with an immunization interval ≤10 years and >10 years, respectively. Among 2-dose recipients, VE was 95.94%(90.69%-98.23%) and 92.89%(83.87%-96.87%) for those with an immunization interval ≤6 years and >6 years, respectively. Logistic regression showed that male students had a higher risk of varicella than female students; prior receipt of two doses of VarV significantly reduced the risk of infection; and the risk increased by 1 year for each additional year between the last immunization and exposure to the index case. The VE of post-exposure vaccination was 90.15% (68.53%-96.92%) among unvaccinated students and 94.88% (89.47%-97.51%) among students who had previously received 1 dose. A single dose of varicella vaccine provides limited long-term protection among high school students, whereas a two-dose regimen offers robust and sustained effectiveness. Routine catch-up vaccination and timely post-exposure vaccination are recommended for the effective control of varicella outbreaks in school settings.

PMID 42553282
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal B vaccine